
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics Inc. is demonstrating a promising outlook due to the advancement of its pipeline candidates, particularly in high-value indications, which suggests potential for significant market opportunities. The company’s valuation assessment currently does not reflect any contribution from SER-270 or other pipeline candidates beyond SER-252, indicating that successful clinical outcomes for SER-270 may lead to substantial upside in future forecasts. Furthermore, the broadening approval footprint of the enFuse product enhances expectations for global acceptance and market penetration of SER-252, reinforcing confidence in the company's growth potential.
Bears say
Serina Therapeutics reported a net loss of $0.64 per share, significantly higher than the previously estimated loss of $0.36 per share, indicating deteriorating financial performance. The company faces multiple risks, including potential delays and failures in advancing its key drug candidate, SER-252, through clinical assessments and regulatory approval processes, which could impact its market viability. Additionally, anticipated commercial uptake may be hindered by increased competition and market dynamics, compounded by possible dilution risks in the near to medium term.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares